A six-year-old boy from Churu district in Rajasthan died at JK Lon Hospital in Jaipur following the use of cough syrup

Spread the Message

Read Time:3 Minute, 58 Second

A six-year-old boy from Churu district in Rajasthan died at JK Lon Hospital in Jaipur after being treated for acute brain fever and complications allegedly following the use of cough syrup at home. This tragic death is part of a series of recent pediatric fatalities linked to dextromethorphan-based cough syrups in Rajasthan and neighboring Madhya Pradesh, raising alarms about the safety and regulation of such medications for children. Parents reported administering cough syrup before the boy’s hospitalisation, but his condition worsened, marked by convulsions and breathing difficulties, ultimately leading to his death despite intensive care and ventilator support.

Key Findings and Developments

Investigations by state health authorities in Rajasthan have been inconclusive about the exact cause of these deaths. Laboratory tests on samples of the implicated cough syrup found no toxic contaminants such as diethylene glycol or ethylene glycol, chemicals known internationally for causing kidney failure and death when adulterated in medicines. The syrup contained dextromethorphan hydrobromide, a common cough suppressant that medical experts say should not be given to children under six years due to safety concerns.

As of early October 2025, Rajasthan has reported four pediatric deaths linked to the cough syrup, and Madhya Pradesh has seen at least nine deaths in related cases, prompting the central government to issue an advisory against the use of cough syrup and cold medicines in children younger than two years, and cautioning their use in children under five. The advisory emphasizes that most childhood coughs are viral and self-limiting, requiring only supportive care such as hydration and rest, rather than medications.

Expert Commentary

Pediatric specialists emphasize caution in the use of dextromethorphan-containing cough syrups for children. Dr. Vivek Jain, Senior Director and Unit Head of Pediatrics at Fortis Hospital, Delhi, explains that the drug acts on the brain’s cough center and, while generally safe in adults, can cause dangerous side effects in children. These include respiratory distress, seizures, and in severe cases, coma or death, especially if overdosed or given without medical supervision. Dr. Jain warns against over-the-counter use and stresses strict adherence to prescribed doses and age limits.

Dr. Jaykishan Tripathi, Consultant Pediatric Critical Care, adds that cough syrups often mask underlying symptoms without treating infections and that the best approach for children’s coughs is identifying and addressing the cause rather than routine medication. The risk of misuse is high because children metabolize drugs differently, making them vulnerable to side effects even at small doses.

Context and Background

Globally and in India, regulatory agencies have cautioned parents against indiscriminate use of cough suppressants in young children. The U.S. Food and Drug Administration (FDA) and pediatric health organizations recommend against over-the-counter cough and cold medications in children under six due to lack of proven benefit and risk of adverse effects including allergic reactions, seizures, and breathing problems.

In the recent Rajasthan and Madhya Pradesh cases, the implicated cough syrups were distributed under government health schemes, revealing gaps in drug safety surveillance and the need for heightened regulatory inspections. Rajasthan authorities have suspended supplies from the manufacturer pending further investigation.

Public Health Implications

These incidents underline the critical need for educating caregivers on safe medication practices for children. Supportive care remains the cornerstone for treating pediatric coughs and colds. Healthcare providers urge parents to seek professional advice before administering any medication and to avoid self-medicating children with syrups, particularly those containing dextromethorphan or similar compounds.

The health ministry’s recent advisory urges stringent prescription practices, better pharmacovigilance, and outreach to inform the public about the risks associated with cough syrups in young children. Given the vulnerability of children’s developing respiratory and nervous systems, caution, supervision, and professional guidance are essential when considering any drug treatment.

Potential Limitations and Counterarguments

While contamination has been ruled out in these cases, the exact cause of death may involve multiple factors including underlying illnesses such as acute brain fever or febrile seizures, which may worsen with inappropriate medication. Also, quality control issues remain under scrutiny with some reports of sub-standard medicines in the market. Further research and forensic investigations are needed to clarify mechanisms of harm and guide safe pediatric cough management policies in India.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.